Different Adaptations of IgG Effector Function in Human and Nonhuman Primates and Implications for Therapeutic Antibody Treatment
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Safety of human therapeutic Abs is generally assessed in nonhuman primates. Whereas IgG1 shows identical FcγR interaction and effector function profile in both species, fundamental differences in the IgG2 and IgG4 Ab subclasses were found between the two species. Granulocytes, the main effector cells against IgG2- and IgG4-opsonized bacteria and parasites, do not express FcγRIIIb, but show higher levels of FcγRII in cynomolgus monkey. In humans, IgG2 and IgG4 adapted a silent Fc region with weak binding to FcγR and effector functions, whereas, in contrast, cynomolgus monkey IgG2 and IgG4 display strong effector function as well as differences in IgG4 Fab arm exchange. To balance this shift toward activation, the cynomolgus inhibitory FcγRIIb shows strongly increased affinity for IgG2. In view of these findings, in vitro and in vivo results for human IgG2 and IgG4 obtained in the cynomolgus monkey have to be cautiously interpreted, whereas effector function-related effects of human IgG1 Abs are expected to be predictable for humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300 · cited 1×
“domain of CD28, the loss of Siglec-5 expression during human evolution (11, 12), or a different expression pattern of CD28 on a specific T cell subset (13).”
BackgroundLoss of Siglec expression on T lymphocytes during human evolution
Nguyen, D. H., Hurtado-Ziola, N., Gagneux, P., & Varki, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510484103 · Cited by 204 · cited 1×
“domain of CD28, the loss of Siglec-5 expression during human evolution (11, 12), or a different expression pattern of CD28 on a specific T cell subset (13).”
BackgroundPreclinical safety testing of monoclonal antibodies: the significance of species relevance
Chapman, K., Pullen, N., Graham, M., & Ragan, I. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2242 · Cited by 121 · cited 1×
“Due to their proximal evolutionary relationship to humans, the most appropriate preclinical model to analyze the therapeutic effect and potential toxicity of human Abs are nonhuman primates (NHP), in particular the cynomolgus monkey (9).”
BackgroundSignaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
Waibler, Z., Sender, L. Y., Merten, C., Hartig, R., Kliche, S., Gunzer, M., Reichardt, P., Kalinke, U., & Schraven, B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001708 · Cited by 79 · cited 1×
“domain of CD28, the loss of Siglec-5 expression during human evolution (11, 12), or a different expression pattern of CD28 on a specific T cell subset (13).”
Background
Cited by
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Moldt, B., Rakasz, E. G., Schultz, N., Chan-Hui, P.-Y., Swiderek, K., Weisgrau, K. L., Piaskowski, S. M., Bergman, Z., Watkins, D. I., Poignard, P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214785109 · Cited by 463
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220145110 · Cited by 339
Smith, B., Kiessling, A., Lledo-Garcia, R., Dixon, K. L., Christodoulou, L., Catley, M. C., Atherfold, P., D’Hooghe, L. E., Finney, H., Greenslade, K., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1505464 · Cited by 117
“The cynomolgus monkey was selected as a suitable species for investigation of the PK, PD and safety of human IgG, and mutants thereof, because human and cynomolgus monkey IgG4 bind comparably to cynomolgus monkey FcRn(26,27) and have similar Fc effector functions.(28)”
Background
Metadata
- Authors
- Warncke, M., Calzascia, T., Coulot, M., Balke, N., Touil, R., Kolbinger, F., & Heusser, C.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-05-01
- Volume
- 188
- Issue
- 9
- Pages
- 4405-4411
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2146998582
- Cited by
- 102
- References
- 5
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Different Adaptations of IgG Effector Function in Human and Nonhuman Primates and Implications for Therapeutic Antibody Treatment. https://app.cochat.ai/papers/10.4049/jimmunol.1200090
- The paper
- Warncke, M., Calzascia, T., Coulot, M., Balke, N., Touil, R., Kolbinger, F., & Heusser, C. (2012). Different Adaptations of IgG Effector Function in Human and Nonhuman Primates and Implications for Therapeutic Antibody Treatment. The Journal of Immunology. https://doi.org/10.4049/jimmunol.1200090
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.